Patients who have a specific type of medical treatment called allo-HCT need to be watched closely for 90 days after the procedure.
Low levels of a protein called serum albumin at day 90 can mean patients are more likely to have serious health problems or die, especially those who had leukemia or a blood disorder.
Researchers found that having low serum albumin and poor health scores at that time can help predict who is at greater risk of complications after treatment.